Associate Professor, Internal Medicine, Ohio State University College of Medicine
Oncology
Dr. Rebecca J. Klisovic, MD
|
|
Give Review
Doctor Rebecca J. Klisovic, MD is an expert in the field of Oncology. He attended The Ohio State University College of Medicine. He received 1 awards: "CMS Meaningful Use Stage 1 Certification". Rebecca Klisovic is a published doctor. He has 35 publications published. The most current publication "Endothelial chimerism in chronic sclerotic-type chronic Graft-versus-Host disease and GVHD-associated angiomatosis." He accepts Medicare.
Publications
- Endothelial chimerism in Chronic sclerotic-type Chronic Graft-versus-Host disease and GVHD-associated angiomatosis.
- Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors.
- Atorvastatin for the Prophylaxis of Acute Graft vs. Host Disease (GVHD) in Patients Undergoing HLA-Matched Related Donor Hematopoietic Stem Cell Transplantation (HSCT).
- Examination of unplanned 30-day readmissions to a comprehensive Cancer hospital.
- Decitabine priming enhances the anti-leukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in Acute myeloid leukemia.
- Lower dose of antithymocyte globulin does not increase Graft-versus-host disease in patients undergoing reduced-intensity conditioning allogeneic hematopoietic stem ce...
- The hematopoietic stem cell transplant comorbidity index can predict for 30-day readmission following autologous stem cell transplant for Lymphoma and multiple myeloma.
- Targeted Delivery of microRNA-29b by Transferrin Conjugated Anionic Lipopolyplex Nanoparticles: A Novel Therapeutic Strategy in Acute Myeloid Leukemia.
- Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: A novel epigenetic-targeting approach in Acute myeloid leukemia.
- In Vivo Quantification of Active Decitabine-Triphosphate Metabolite: A Novel Pharmacoanalytical Endpoint for Optimization of Hypomethylating Therapy in Acute Myeloid L...
- Genome-wide methylation profiling in decitabine-treated patients with Acute myeloid leukemia.
- Pre-clinical activity of a novel CRM1 inhibitor in Acute myeloid leukemia.
- RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine in Acute myeloid leukemia.
- Dose escalation of lenalidomide in relapsed or refractory Acute leukemias.
- Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine.
- Phase I study of GTI-2040, an antisense to ribonucleotide reductase, in combination with high-dose cytarabine in patients with Acute myeloid leukemia.
- A phase I biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase 1, in patients with high-risk myelodysplasia and Acute myeloid leukemia.
- Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-kappaB-dependent DNA methyltransferase activity in Acute myeloid leuk...
- Phase I study of decitabine alone or in combination with valproic acid in Acute myeloid leukemia.
- Hyperglycemia in patients with Acute myeloid leukemia is associated with increased hospital mortality.
- Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and Cellular differentiation in AML1/ETO-positiv...
- Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with Acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, ...
- The MLL partial tandem duplication: evidence for recessive gain-of-function in Acute myeloid leukemia identifies a novel patient subgroup for molecular-targeted therapy.
- Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with Acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical ac...
- A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and Acute myeloid leukemia.
- Characterization of in vitro and in vivo hypomethylating effects of decitabine in Acute myeloid leukemia by a rapid, specific and sensitive LC-MS/MS method.
- Quantification of valproic acid and its metabolite 2-propyl-4-pentenoic acid in human plasma using HPLC-MS/MS.
- Addition of infliximab to standard Acute graft-versus-host disease prophylaxis following allogeneic peripheral blood cell transplantation.
- Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplanta...
- A LC-MS/MS method for the analysis of intraCellular nucleoside triphosphate levels.
- Enzyme kinetics of GTI-2040, a phosphorothioate oligonucleotide targeting ribonucleotide reductase.
- Biochemical modulation of aracytidine (Ara-C) effects by GTI-2040, a ribonucleotide reductase inhibitor, in K562 human Leukemia cells.
- Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory Acute leukemias.
- Granulocyte Colony-Stimulating Factor-Mobilized Allografts Contain Activated Immune Cell Subsets Associated with Risk of Acute and Chronic Graft-versus-Host Disease.
Schools
Ohio State University College Of Medicine and Public Health
Unc
Oh State University
Procedures Preformed
- Bone Marrow Transplant
- HPC Transplantation (Stem Cell Transplant)
Conditions Treated
- Acute Leukemia
- Anemia
- Antiphospholipid Syndrome (APS)
- Breast Cancer
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Anthem Blue Cross Blue Shield HMO
- Anthem Blue Cross Blue Shield PPO
- Blue Card PPO
- Blue Cross Blue Shield of Illinois PPO
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Coventry Health America PPO
- First Health (Coventry Health Care) PPO
- Medical Mutual of Ohio POS
- MultiPlan PPO
- PHCS Network PPO
- Mutual of Omaha
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
Ohio State University Hospital -
University of North Carolina Hospitals -
The Ohio State University College of Medicine
Hospital
-
Ohio State University Wexner Medical Center
Drug Facts
| NPI NUMBER | 1417962945 | |
| NPPES Provider LastName | KLISOVIC | |
| NPPES Provider FirstName | REBECCA | |
| NPPES Provider ZIPCode | 432101280 | |
| NPPES Provider State | OH | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 348.0 | |
| Distinct Opioid Count | 3.0 | |
| Opioid Claim Count | 93.0 | |
| Percent Opioid Claims | 26.72 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1417962945 |
| Last Name Of The Provider | KLISOVIC |
| First Name Of The Provider | REBECCA |
| View All |
Similar Doctors
|
Dr. Mark S. Collins, MD |
|
|
Dr. Thomas J. Sweeney, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Arvinder S. Bhinder, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Robert Wesolowski, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Christopher S. George, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Erin M. Olson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Brent C. Behrens, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jennifer A. Woyach, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Elizabeth M. Yu, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Maura L. Gillison, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|